Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 162 participants.
Also called NCT04841096
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 162 participants
- Registry
-
NCT04841096
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Mexico
- Registry status
- Completed
Technical summary
Registry record NCT04841096. Randomized; double masking; primary purpose treatment. Start 2023-03-21 (actual); primary completion 2024-03-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- A1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)
- Intervention (Drug)
- B2=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)
- Intervention (Drug)
- (A2) Glimepiride/Vildagliptin/Metformin
- Intervention (Drug)
- (B2) Glimepiride/Vildagliptin/Metformin
- Lead sponsor
- Laboratorios Silanes S.A. de C.V.
Record details
- Record id
cardio:ct-nct04841096- Content hash
bb84830aa903fd599755bea93ee878d4f64ab23323d2b380a7729dfc4a0b74d4